# Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

> **NCT04531046** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 62 (actual)

## Conditions studied

- B-Cell Lymphoma Refractory
- B-cell Lymphoma Recurrent

## Interventions

- **DRUG:** axicabtagene ciloleucel

## Key facts

- **NCT ID:** NCT04531046
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-10
- **Primary completion:** 2022-04-19
- **Final completion:** 2026-06
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531046, "Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04531046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*